initi coverag
ard new way open old door initi overweight pt
invest summari initi coverag ard share ow
rate pt ard focus discoveri develop
target immunotherapi use fulli human monoclon antibodi mab
treat life-threaten infect expect upward earn revis multipl
expans move ard stock higher driven success
advanc ard pipelin
 ard mad mab compani flagship drug
treatment pneumonia expect interim phase data
compani object chang way physician treat infect current
approv antibiot use treat staphylococcu aureu includ vancomycin
linezolid televancin ard expect adjunct therapi
antibiot improv outcom patient expect
reimburs drg longer term paid like
oncolog rare/orphan diseas drug ard expect enrol first subject
plan includ interim data readout complet
enrol could also potenti use treat bloodstream
infect given long half life
 ard sever potenti shot goal ard product portfolio includ
three mid-to-late-stag mab aerucin
fulli human mab target pseudomona aeruginosa aeruginosa
ard develop initi adjunct immunotherapi
soc antibiot treat acut pneumonia caus aeruginosa infect
compani initi global phase pivot trial expect report
data grant track design fda
aerumab fulli human immunoglobulin igm mab target
 aeruginosa serotyp ard complet phase trial phase trial
plan initi phase pivot trial grant
orphan drug design eu
free call option early-stag asset ard three pre-clin compound
aim treat infect caus acinetobact baumannii
fulli human mab neutral divers clinic isol respiratori
syncyti viru rsv panaecin broad-spectrum small
molecul anti-infect develop addit compani target
mab product candid current late preclin studi
fund cystic fibrosi foundat phase trial
 valuat use blend ev/ebitda dcf bull bear base case
analys arriv pt
disclosur section may found page
ard new way open old door initi overweight
tabl content
compani descript aridi biopharmaceut compani focus
discoveri develop target immunotherapi use
fulli human monoclon antibodi mab treat life-threaten
aridi also three preclin anti-
infect drug candid
proprietari platform technolog mabigx discov rare potent
human mab patient
invest summari initi coverag ard share
ow rate pt ard focus discoveri
develop target
monoclon antibodi mab treat life-threaten infect
expect upward earn revis multipl expans move
ard stock higher driven success
advanc ard pipelin
reason buy ard stock
target immunotherapi use fulli human mab treat life-
threaten infect could address unmet need associ
free call option preclin asset
compet crowd market mani establish player
product meaning higher price point
lot preced payor reimburs use
mab treat infect
compet directli astrazeneca/medimmun cover
potenti other
use blend dcf ev/ebitda bull bear
base case analys arriv pt
aridiss ev/sal compar favor
 compani compar averag ev/sal
aridiss market capit compar
favor similar publicli trade compani
averag market capit
expect recent ipo rais get compani
initi first two pivot phase trial ar-
expect interim data top-
line data
phase data
advanc clinic preclin pipelin
candid
think target immunotherapi use fulli human mab treat life-threaten infect could address
unmet need associ tradit antibiot underappreci investor
compani object chang way physician treat infect think make
interest invest opportun given leadership chang treatment paradigm
current approv antibiot use treat staphylococcu aureu gram posit bacteria includ vancomycin
linezolid televancin
icu patient infect one bug
aridi expect adjunct therapi antibiot improv outcom patient
cost treat patient icu aridi believ payor would accept cost
per cours treatment
time peak sale potenti could year longer normal antibiot usual year
approv aridi expect show clear pharmacoeconom benefit drug expect
reimburs drg longer term paid like oncolog
first phase clinic trial random double-blind placebo-control activ compar
mg/kg plu soc vs placebo plu soc aridi plan enrol vap patient clinic site
countri assum treatment effect clinic cure vs activ drug-treat patient would
provid power demonstr statist signific result aridi expect enrol first subject
plan includ interim data readout complet enrol
think aridi interest compani consolid space large-cap pharma compani interest
anti-infect includ overweight merck cover astrazeneca cover sanofi
also think could potenti use treat bloodstream infect given long half life
aridiss product portfolio includ three mid-to-late-stag mab
make compel invest opportun view
competitor one drug develop
salvecin tosatoxumab fulli human immunoglobulin mab target hap
vap aureu alphatoxin aridi develop initi adjunct immunotherapi
combin standard care soc antibiot treat acut pneumonia caus aureu
infect aridi expect initi phase pivot trial grant track
design fda orphan drug design eu aridi file orphan drug
design estim peak sale could drug
aerucin fulli human mab target pseudomona aeruginosa aeruginosa aridi
develop initi adjunct immunotherapi soc antibiot treat acut
pneumonia caus aeruginosa infect compani initi global phase pivot trial
expect report data grant track design fda
estim peak sale could drug
aerumab fulli human immunoglobulin igm mab target aeruginosa serotyp
aridi complet phase trial phase trial plan initi phase pivot trial
grant orphan drug design eu estim peak
sale could sever hundr million dollar drug
free call option preclin asset asset could
larger aridiss mid-to-late-stag pipelin view
aridiss mab discoveri program aim treat infect caus acinetobact
baumannii compani use mabigx technolog identifi novel target select sever fulli
human mab candid intend select develop candid addit preclin studi
fulli human mab neutral divers clinic isol respiratori syncyti viru
rsv vivo preclin studi head-to-head comparison studi shown
time potent synagi current market drug pediatr rsv bind rsv strain
resist synagi
panaecin broad spectrum small molecul anti-infect develop addit
compani target mab product candid current late preclin studi
fund cystic fibrosi foundat phase trial compani expect ind file
initi phase trial healthi adult cystic fibrosi patient
compet crowd market mani establish player meaning higher price point
alreadi mani approv gener brand antibiot market market
compani better-capit and/or deeper pocket aridi gener
brand antibiot price point expect aridi could potenti charg
drug said aridiss drug could address mani unmet need current market drug
lot preced payor reimburs use mab treat infect
current approv anti-infect immunotherapi drug market therefor
unclear payor reimburs drug avail market posit
pharmacoeconom data becom avail aridiss drug approv could move
reimburs drg way oncolog rare/orphan diseas drug reimburs
could acceler uptak product
compet directli astrazeneca/medimmun potenti other
compet directli aridi
astrazeneca/mediummun potenti arsani aridi expect enter market earli
clear yet competitor plan receiv approv aridi believ compani
fto freedom oper
aridi cantor fitzgerald research
use blend ev/ebitda dcf bull bear base case analys arriv pt
dcf analysi result price per share use exit multipl discount rate
ev/ebitda analysi result price per share
bull bear base case analysi forecast likelihood stock next month
aridiss ev/sal compar favor compani compar averag ev/sal
aridiss market capit compar favor similar publicli trade compani
averag market capit
exhibit bull bear base case analysi
cantor fitzgerald research compani reportsbul data better expectedexpand sale globallypipelin advanc clinic pre-clin asset better scenario data in-lin expectationsexpand sale globallypipelin advanc clinic pre-clin asset in-lin scenario data primarili drugpipelin advanc clinic pre-clin asset scenario aridi equiti compani compar
aridiss forward ev/ebitda compar favor peer averag
tickercompanypric cap mm debt/ ev/ ev/ price/ yield yield ep gr ratepeg ratio jone industri vector large-cap pharmabmybristol myer specialti large-cap device/hospit supplyabtabbott factset cantor fitzgerald estim factset compani coverag mark ep estim adjust non-oper item debt/ebitda estim ebitda arithmet averag chang stock aridi compani compar
aridiss ev/sal compar favor compani compar averag ev/sal
yearbuyersellerev mm ev/salesev/ companyrempex infecti diseas compani report aridi market cap similar publicli trade compani
aridiss market cap compar favor similar publicli trade compani averag
exhibit overview similar publicli trade compani
market cap
focus develop mab immunotherapi target
focus discoveri develop antibiot
focus develop new anti-infect
potenti transform standard care save
focus discov develop commerci
differenti anti-infect acut care select
commun set meet critic medic need
treatment bacteri infecti diseas
focus develop novel antibiot focu
pleuromutilin new class antibiot system
administr human acquir zavant add
contepo product portfolio treat cuti
focus develop commerci
focus drug target infecti diseas
difficult treat condit
earli oct
sarecyclin acn vulgari nda review
focus identifi develop commerci
oral gram phase move directli phase
novel treatment mdr bacteri infect
focus use proprietari chemistri technolog creat
novel antibiot seriou life-threaten mdr
factset compani present websit file
exclud arsani calcul averag market cap given compani announc interim look determin futil phase trial
next import catalyst forese compani
initi first two pivot phase trial
phase data
advanc clinic preclin pipelin candid
exhibit catalyst event calendar
datedriverupcom citrat cf ind citrat cf initi phase pneumonia initi first phase pneumonia/cf phase pneumonia interim phase citrat cf phase hap/vap initi phase citrat cf phase pneumonia complet enrol first phase pneumonia phase patent patent citrat cf patent expiresourc cantor fitzgerald research compani report aridi compani overview pipelin
aridi divers pipelin mid-to-late-stag well preclin asset therefor believ investor
compani mani potenti opportun earn good return invest
view market opportun aridi driven two factor
drug resist advers impact human microbiom frequent use broad-
spectrum antibiot increas need target narrow-spectrum anti-infect
believ aridi offer novel solut problem target immunotherapi
abil identifi infection-caus agent significantli improv recent year
avail prolifer rapid diagnost test mean physician screen
right patient treat aridiss drug
believ treatment infecti diseas experi paradigm shift broad-spectrum
antibiot util narrow target anti-infect opportun still appear
underappreci street
mab offer signific market differenti crowd highli competit
mab more-predict attract safeti profil design kill via immunolog moa
mechan action differ moa antibiot drive resist
mab dose frequenc twice month may requir singl administr
treatment hospital-acquir pneumonia
aridiss mab use adjunct therapi combin antibiot mean
directli compet antibiot offer medic benefit patient econom
benefit hospit improv mortal outcom reduc time clinic cure
length hospit icu stay
aridi design clinic studi use superior primari end point differ
antibiot product use non-inferior clinic trial design
aridiss initi focu respiratori infect icu compani product target bacteri
pneumonia caus specif agent high preval base due dilig still
unmet need new drug
exhibit agent target aridiss product candid
estim follow address market
patient us eu japan
patient us eu japan
patient us eu japan
aridi compani overview hap/vap caus aureu
see aridi novel approach treat infect
aureu alphatoxin toxin produc aureu strain caus destruct human cell
tissu develop adjunct therapi soc standard care antibiot
bind alphatoxin high affin prevent assembl activ complex
prevent alphatoxin-medi breakdown cell membran erythrocyt human lung cell
immun cell lymphocyt
shown bind aureu clinic isol test test vitro studi
double-blind placebo-control phase studi test adjunct therapi soc
antibiot patient sever hap caus aureu demonstr posit result
exhibit phase phase trial design
phase trial trialstatuscompleteexpect initi last subject expect first two pivot trial populationpati hap vap caus aureushap/vap microbiolog evalu designrandom double-blind placebo-control activ compar singl ascend doserandom double-blind placebo-control activ comparatorpurposedesign primarili address safeti pharmacokinet power achiev statist signific multipl exploratori endpoint assess efficaci relat outcom paramet includ mortal clinic cure rate time extub microbiolog erad reduct number hospit icu dayssafeti efficaci antibiot alon placebo mg/kg mg/kg mg/kg mg/kg antibiot alon placebosoc mg/kg number site across eu site countriessafeti pharmacokineticswel toler deem relat studi drug relat immunogen observ one subject relat ae signific differ mortal group death deem unrel treatment profil consist human plasma half-lif day support single-dos administrationhav reach agreement fda size safeti databas requir approv plan includ follow safeti endpoint immunogen standard safeti lab test clinic efficacytim intub day show decreas length time patient remain intub patient treat soc compar placebo socventil time reduc patient receiv soc compar receiv placebo socerad presum erad cure ofpneumonia observ patient treat plu soc ten subject treat placebo plu soc primari efficaci endpoint ventil time clinic cureendpoint may includ mortal rate microbiolog erad reduct time microbiolog erad and/or overal durat icu hospit stayaridi believ improv soc placebo soc clinic meaning septemb
compel opportun view drug develop first-lin adjunct
therapi soc antibiot
demonstr broad vivo vitro protect varieti aeruginosa strain
test bind target aeruginosa algin cell surfac polysaccharid involv
protect human immun system
algin product hallmark chronic aeruginosa infect progress declin lung
function patient cystic fibrosi cf aridi believ potenti develop
therapi treat aeruginosa infect cf patient indic plan explor
exhibit mechan action
aridi compani overview phase preclin data
phase trial healthi volunt assign one three cohort observ
day well-toler test dose level total advers event
deem non-remark typic mab infus
exhibit phase data support safeti pk profil
aridi compani overview phase preclin data
vitro studi demonstr abil bind kill wide rang
aeruginosa clinic isol pneumonia patient includ strain vari level
antibiot resist tobi tobramycin cayston aztreonam suggest activ
independ antibiot resist statu given strain
one mice studi combin meropenem show lower bacteri load either
current phase trial hap/vap patient infect aeruginosa data
expect
exhibit phase trial design
phase trial phase trial data expect first two pivot studi requir regulatori approv populationpati hap vap caus gram-neg aeruginosadesignrandom double-blind placebo-control activ compar singl ascend dosepurposearidi plan expand studi power detect differ primari endpoint clinic cure rate day p-valu interim safeti efficaci readout data enough patient record provid power treatmentsplacebo antibiot alon mg/kg site across countri us eu asia primari endpointclin cure ratesecondari endpointal caus mortalitytim clinic resolutiontim remov ventilatorday icuhospit daysmicrobiolog cureantibiot utilizationsourc cantor fitzgerald research compani report aridi compani overview hap/vap caus aeruginosa serotyp
round aridiss mid-to-late-stag pipelin view
 aeruginosa serotyp account aeruginosa hai bind aeruginosa
bacteria improv immun recognit destruct circul human phagocyt make
effect mdr isol
exhibit mechan action
think good idea aridi incorpor companion diagnost test base polymeras
chain reaction pcr technolog rapidli identifi aeruginosa serotyp strain order
identifi patient like respond
phase trial healthi adult open-label phase trial three singl
dose pneumonia patient shown well-toler healthi adult
hap/vap patient
comparison patient treat phase studi contemporan control cohort
suggest therapi may improv surviv cure rate index pneumonia time cure
aridi expect initi pivot phase trial
exhibit phase trial design
phase trialstatusiniti expect patientsdesignrandom double-blind placebo-control adjunct soc antibioticspurposeprimari efficaci endpoint includ clinic cure all-caus mortal pneumonia-rel mortal also assess microbiolog endpoint well select pharmacoeconom endpoint pharmacokinet aridi compani overview previou clinic trial
exhibit phase phase result
phase trialpopulationhealthi patientsdesignsingle-cent double-blind dose escal studi evalu safeti pharmacokinet mg/kg mg/kg mg/kg mg/kg mg/kg placebo mg/kg placebo mg/kg placebo mg/kg placebo antibiot per protocol pp alone- contemporan cohort studi mortal time initi clinic resolut pneumonia daystim ventil time icu daysiniti clinic resolut pneumonia resolut pneumonia day mortal time initi clinic resolut pneumonia daystim ventil time icu daysiniti clinic resolut pneumonia resolut pneumonia day event infus well toler complet without interrupt observ eight subject report total nine seven mild two moder one eight subject receiv placebo report one mild one moder ae ae resolv without sequela correl ae incid dose sourc cantor fitzgerald research compani reportspati exclus pp popul analysi follow -one patient evolv cholestasi prior studi drug administr receiv one dose worsen cholestasi follow neutropenia gastrointestin bleed preclud administr patient die day multi-organ failur link event -increas prothrombin time cardiac arrest deem possibl relat report one patient patient receiv one dose studi drug die day second cardiac arrest judg unrel -two patient exclud occurr unrel one patient die day due gastrointestin hemorrhag one patient exclud suffer haemolysi due mismatch blood group antigen transfus two patient receiv one dose studi drug resultspk mean rang hour roughli coincid report half-lif day igm mabspk patient given antibiot per protocol mean hour similar phase phase trial nosocomi aeruginosa serotyp hap/vapmulti-cent open pilot studi evalu safeti pharmacokinet least one dose mg/kg given everi hour least one dose iv mg/kg given everi patient intent-to-treat group receiv full three-dos treatment per-protocol group compar group consist patient fulfil inclus exclus criteria phase studi could receiv aridi compani overview preclin candid
compani three addit asset variou stage preclin develop think could
larger product mid-to-late-stag pipelin
exhibit pipelin preclin candid
broad-spectrum small molecul anti-infect human mab human mabmoaact iron analog inhibit iron-depend metabol pathway requir pathogen prevent biofilm formationdirect f-protein respiratori syncyti viru rsv identifi eight novel anti-a baumannii drug target screen baumannii infect patient rare b-cell select number lead mab candid direct novel put target ona baumannii targetcyst fibrosi cf respiratori syncyti viru rsv infect caus gram-neg baumanniistatuscomplet preclin anim studi phase trial expect initi preclin developmentmab discoveri programbenefitsbroad activ gram-neg gram-posit bacteria includ difficult-to-treat aeruginosa cepaciaeffect drug-resist strain presenc bacteri biofilmsveri low non-detect incid drug resistanceengin long plasma half-lif suffici last durat rsv infect season singl dosewa isol b-cell infant infect rsv function optim immun system broadli neutral rsv clinic isol includ strain resist sole soc mab synagi palivizumab address increas multi-drug resist clinic isol baumanniisourc cantor fitzgerald research compani report septemb
think aridi abl leverag mabigx fulli human antibodi discoveri platform expand
pipelin base due dilig believ mabigx offer follow competit advantag
enabl compani screen identifi function optim b-cell patient directli
manufactur mab one year faster tradit technolog
broad applic produc immunolog clinic relev product candid across
relev immunoglobulin isotyp includ igg iga igm ige antibodi mean most-
relev most-effect human antibodi specif pathogen isol select
discoveri mab product candid high efficaci due recognit epitop relev
gener product candid well-toler potenti multipl
administr due low immunogen nomin abil provok anti-drug immun respons
abil rapidli progress clinic manufactur avoid need time-consum
recombin antibodi engin process product cell line
like mani development-stag compani aridi oper manufactur facil
product clinic commerci quantiti product candid current plan build
clinic commercial-scal manufactur capabl
compani plan use commerci contract manufactur partner larg bioreactor
aridi develop product cell line support late-stag clinic test
commerci base chines hamster ovari cho cell technolog most-matur wide
use cell-cultur technolog manufactur mab product
aridi plan identifi util contract manufactur organ experi
use cho cell launch commerci product facil subsequ decid whether
explor build company-own manufactur facil
exhibit manufactur statu product candid
creat new cho cell line maxim product quantiti scale manufactur process clinic drug product manufactur scale contract manufactur partner catal pharma solut madison wi manufactur process scale scale support licensur commerci launch clinic manufactur scale cell cultur mab purif process develop clinic materi manufactur contract manufactur massbiolog mattapan scale support phase studi aridi creat new cho cell line maxim product quantiti cho line use manufactur clinic trial materi phase pivot trial support commerci manufactur clinic manufactur scale cell cultur mab purif process develop transfer clinic manufactur sanquin pharmaceut servic amsterdam netherland rentschler biotechnologi gmbh laupheim germani produc clinic trial materi addit clinic materi need support phase phase clinic studi aridi develop simpl manufactur process produc pure gallium citrat use gallium nitrat ammonium citrat manufactur process transfer contract manufactur regi technolog inc morton grove il implement scale gmp aridi believ materi suffici support clinic trial need phase cantor fitzgerald research compani report septemb
base due dilig aridiss main competitor includ medimmun astrazeneca cover
potenti arsani asn overweight
exhibit detail aridiss competitor develop program
think aridi largest most-compel pipelin
exhibit compar contrast compani opportun
exhibit competitor develop
aridi pg compani websit
drugcompanydevelop aureu cfp aeruginosa aeruginosa lp fail hap/vap aureu alpha-toxin suvratoxumab medimmun aureu aeruginosa psl pcrvsourc cantor fitzgerald research compani report aridi compani overview intellectu properti market exclus
aridi robust ip portfolio view aridiss patent estat includ issu
patent pend patent applic four aridi either own
exclus commerci licens either entireti within field use
exhibit aridi ip market exclus product candid
grantedeu us russia china israel japan pend canada korea india brazilu euu eu canada europ china india israel japanu eu australia canada china hong kong japan mexico new zealandon us pend applic canada china eu india usaustralia china eu us pend canada china division japan div us div patent typecomposit method use cover mab bind aureu alpha-toxincomposit cell line produc humab bind aeruginosa alginatecomposit cell line produc humab bind aeruginosa lp matter method use anti-infect indicationsmethod produc certain antibodi specif region rsv protein method treat prevent rsv infect antibodiesclaim includ direct certainvaccin composit mab outer membran protein targetsyear patent pend pend track design fda orphan drug design eu appli us fast-track design fdaorphan drug design us eu -- portfolio complement patent famili in-licens univers chicago titl method composit relat immun staphylococc lung diseas condit patent famili includ ten patent grant jurisdict includ australia china eu japan korea us six patent applic pend brazil canada china hong kong japan us patent famili expect expir estat includ two patent famili exclus in-licens brigham women hospit harvard first famili titl aeruginosa mucoid exopolysaccharid specif bind peptid compris three issu us patent expect expir second famili titl method composit relat mannuron acid specif bind peptid compris one european patent expect expir pend patent us upon issuanc expir patent estat includ three patent famili two aridi own one in-licens univers iowa research foundat tbe in-licens issu patent expect expir aridi compani overview licens agreement
exhibit detail aridiss notabl licens agreement
univers chicago co-exclus world-wide licens agreement women hospit exclus patent licens agreement iowa research foundat exclus patent licens agreement young univers exclus patent licens agreement biotech ltd corpor licens agreement mabigx oblig pay low singl digit percentag royalti net sale licens product minimum royalti requir per year sale begin addit certain mileston paymentsoblig pay low singl digit percentag royalti net sale sale commerci licens product process certain mileston payment aridi respons dilig prosecut maintain licens patent right sole cost expenseoblig pay low singl digit percentag royalti net sale sale commerci licens product process certain mileston payment aridi respons dilig prosecut maintain licens uirf patent right sole cost expenseoblig pay low singl digit percentag royalti adjust gross sale defin byu agreement certain payment byu respons dilig prosecut maintain licens byu patent right aridi reimburs one-third costsoblig pay fix purchas price fulli paid declin scale low doubl digit low singl digit percentag royalti gross licens revenu either licens asset net sale revenu actual receiv aridi maximum septemb
aridi experienc manag team includ believ right leader move
titl
ceo cso director
dr truong serv ceo cso head sinc year experi biopharmaceut drug
develop held posit increas respons transform pharmaceut inc genemedicin inc aviron inc
medimmun sold astrazeneca receiv ph pharmacolog molecular scienc john hopkin univers school
medicin biochemistri brandei univers
mr kurland serv cfo sinc juli serv compani board director august juli
season financi execut year experi pharmaceut industri prior join aridi vice-president financ cfo
secretari xoma corpor decemb march mr kurland serv cfo
bayhil inc corcept inc genitop corp serv senior vice-president cfo aviron
acquir medimmun mr kurland vice-president cfo protein design lab inc antibodi
design compani serv vice-president cfo appli immun scienc inc also held number financi
manag posit syntex corpor pharmaceut compani acquir roch includ vice presid control
mr kurland receiv univers chicago busi econom
lehigh univers
dr dummer hire aridiss februari dr dummer year clinic trial drug develop
experi recent vice-president clinic develop biomarin pharmaceut inc led clinic develop
approv vimizim elosulfas alpha biomarin lead market compound year prior held variou senior role
clinic research develop genentech inc also spent three year studi scripp research institut la jolla
california dr dummer author co-author peer-review journal articl board-certifi clinic
dermatologist allergist/immunologist earn degre ph medic scienc technic univers
million compound-annual-growth-rate year end decemb oper incom avail common share chang yoytot cantor fitzgerald research compani conserv assum tax rate upon aridi disclos quarterli number number base number number first nine month provid aridi divid first nine month number equal aridi margin analysi
cantor fitzgerald research compani report aridi quarterli sale
million year end decemb chang cantor fitzgerald research compani report aridi annual sale
cantor fitzgerald research compani reportsyear end decemb aridi
million year end decemb flow provid oper activ net depreci net chang work net cash provid oper flow invest activitiespurchas net proce sale assets- acquisit net cash acquired- other- net cash use invest flow financ activ repay issuanc long term proce issuanc stock net cash use provid financ net decreas increas cash equival begin equival end sourc cantor fitzgerald research compani report aridi balanc sheet
million year end decemb account receiv less allow doubt inventories- current total current plant properti identifi goodwill- total total liabil sharehold equityaccount payabl accru total current long term debt liabilities- total sharehold total stockhold non-controlling total liabil stockhold sourc cantor fitzgerald research compani report aridi market model
salvecin usgram-posit aureus-induc hap/vap case market us cost treatment price salvecin revenu cantor fitzgerald research compani includ hcap would upsid estim year end decemb salvecin eu japangram-posit aureus-induc hap/vap case eu market ex-u cost treatment price salvecin revenu cantor fitzgerald research compani includ hcap would upsid estim year end decemb aridi market model
aerucin usgram-neg aeruginosa-induc hap/vap case suscept total treatabl market cost treatment price aerucin revenu ou royalti cantor fitzgerald research compani includ hcap would upsid estim year end decemb aerucin eu japangram-neg aeruginosa-induc hap/vap case eu suscept total treatabl market cost treatment price aerucin revenu ou royalti cantor fitzgerald research compani includ hcap would upsid estim year end decemb aridi market model
aerumab ushap/vap case caus aeruginosa market cost treatment price aerumab revenu ou royalti cantor fitzgerald research compani includ hcap would upsid estim year end decemb aerumab eu japanhap/vap case caus aeruginosa eu market cost treatment price aerumab revenu ou royalti cantor fitzgerald research compani includ hcap would upsid estim year end decemb septemb
inc biopharmaceut compani focus develop novel differenti therapi infecti
diseas aridi product portfolio includ three clinic stage monoclon antibodi three addit
preclin anti-infect drug candid compani also proprietari platform technolog mabigx
discov rare potent human mab patient
